MoonLake Immunotherapeutics/$MLTX
1D1W1MYTD1Y5YMAX
Capital at risk
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
- Ticker
- $MLTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 130
- Headquarters
- Zug, Switzerland
- Website
- www.moonlaketx.com
MLTX Metrics
BasicAdvanced
$1.1B
-
-$3.81
1.07
-
Price and volume
Market cap
$1.1B
Beta
1.07
52-week high
$62.75
52-week low
$5.95
Average daily volume
1.4M
Financial strength
Current ratio
12.558
Quick ratio
11.975
Long term debt to equity
0.234
Total debt to equity
0.237
Interest coverage (TTM)
-26.59%
Profitability
EBITDA (TTM)
-265.099
Effective tax rate (TTM)
-0.41%
Management effectiveness
Return on assets (TTM)
-32.44%
Return on equity (TTM)
-67.47%
Valuation
Price to book
2.48
Price to tangible book (TTM)
2.48
Price to free cash flow (TTM)
-3.893
Free cash flow yield (TTM)
-25.69%
Free cash flow per share (TTM)
-3.257
Growth
Earnings per share change (TTM)
36.65%
3-year earnings per share growth (CAGR)
48.70%
Bulls say / Bears say
MoonLake secured a positive final pre-BLA meeting with the FDA for sonelokimab in hidradenitis suppurativa, aligning on submission plans and label strategy including adolescent data and clearing the path for a BLA submission by end-September 2026. (GlobeNewswire)
The Phase 3 IZAR-1 trial in biologic-naïve psoriatic arthritis met all primary and key secondary endpoints at Week 16 for the 60 mg dose of sonelokimab, demonstrating robust efficacy in a registrational setting. (GlobeNewswire)
As of June 30, 2026, MoonLake held $537 million in cash, cash equivalents, and short-term marketable securities with sufficient runway to mid-2028, supported by up to $400 million in non-dilutive funds. (GlobeNewswire)
MoonLake reported a net loss of $61.8 million for Q2 2026, underscoring its continued lack of profitability. (GlobeNewswire)
Quarterly R&D expenses remained high at $50.2 million in Q2 2026, reflecting a substantial cash burn that may pressure its cash runway. (GlobeNewswire)
In June 2026, MoonLake announced a proposed $150 million public offering of Class A ordinary shares, signalling reliance on dilutive equity financing and potential shareholder dilution. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2026.
Upcoming events
No upcoming events
MLTX News
AllArticlesVideos
Funds containing MLTX
AllEURGBPUSD
Fund name | Fund size | $MLTX weighting |
|---|---|---|
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.02% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.02% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.